RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

10X Genomics EBIT 2024

10X Genomics EBIT

-199.53 M USD

10X Genomics Dividend yield

Ticker

TXG

ISIN

US88025U1097

WKN

A2PPQJ

In 2024, 10X Genomics's EBIT was -199.53 M USD, a -22.04% increase from the -255.93 M USD EBIT recorded in the previous year.

The 10X Genomics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e227.05
2027e114.13
2026e-28.86
2025e-113.11
2024e-199.53
2023-255.93
2022-167.9
2021-52.3
2020-531.6
2019-30.6
2018-110.8
2017-18.4

10X Genomics Aktienanalyse

What does 10X Genomics do?

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing 10X Genomics's EBIT

10X Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of 10X Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

10X Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in 10X Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about 10X Genomics Stock

How much did 10X Genomics achieve in EBIT for the current year?

In the current year, 10X Genomics has achieved an EBIT of -199.53 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company 10X Genomics.

How has the EBIT of 10X Genomics developed in recent years?

The EBIT of 10X Genomics has increased by -22.037% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company 10X Genomics?

The EBIT of 10X Genomics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does 10X Genomics pay?

Over the past 12 months, 10X Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 10X Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of 10X Genomics?

The current dividend yield of 10X Genomics is .

When does 10X Genomics pay dividends?

10X Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 10X Genomics?

10X Genomics paid dividends every year for the past 0 years.

What is the dividend of 10X Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 10X Genomics located?

10X Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von 10X Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 10X Genomics from 4/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2024.

When did 10X Genomics pay the last dividend?

The last dividend was paid out on 4/27/2024.

What was the dividend of 10X Genomics in the year 2023?

In the year 2023, 10X Genomics distributed 0 USD as dividends.

In which currency does 10X Genomics pay out the dividend?

The dividends of 10X Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von 10X Genomics

Our stock analysis for 10X Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 10X Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.